Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Robinson

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
The American Journal of Gastroenterology|November 8, 2011
When meta-analysis misleadsMei Yang, Anne M Robinson, Paul F Pollack
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|January 9, 2009
Nasal pathophysiology and its relationship to the female ovarian hormonesCarl M Philpott, Anne M Robinson, George E Murty
Current Medical Research and Opinion|August 4, 2011
A practical, evidence-based guide to the use of adalimumab in Crohn's diseaseDavid T Rubin, Remo Panaccione, Jingdong Chao, et al.
Lancet (London, England)|April 21, 2018
Clinical disease activity in the CALM study - Authors' replyJean-Frédéric Colombel, Remo Panaccione, Joel Petersson, et al.
American Journal of Rhinology|January 19, 2008
The effect of female hormone manipulation on nasal physiologyAnne M Robinson, Carl M Philpott, Julian A Gaskin, et al.
Inflammatory Bowel Diseases|October 25, 2011
Therapeutic drug monitoring of biologics for inflammatory bowel diseaseJean-Frédéric Colombel, Brian G Feagan, William J Sandborn, et al.
Inflammatory Bowel Diseases|February 26, 2011
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARERobert Löfberg, Edouard V Louis, Walter Reinisch, et al.
Inflammatory Bowel Diseases|May 13, 2009
Adalimumab safety in global clinical trials of patients with Crohn's diseaseJean-Frédéric Colombel, William J Sandborn, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|March 23, 2013
Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trialsWilliam J Sandborn, Jean-Frederic Colombel, Julian Panés, et al.
Journal of Crohn'S & Colitis|April 27, 2018
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE TrialsRemo Panaccione, William J Sandborn, Geert D'Haens, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
The American Journal of Gastroenterology|November 8, 2011
When meta-analysis misleadsMei Yang, Anne M Robinson, Paul F Pollack
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|January 9, 2009
Nasal pathophysiology and its relationship to the female ovarian hormonesCarl M Philpott, Anne M Robinson, George E Murty
Current Medical Research and Opinion|August 4, 2011
A practical, evidence-based guide to the use of adalimumab in Crohn's diseaseDavid T Rubin, Remo Panaccione, Jingdong Chao, et al.
Lancet (London, England)|April 21, 2018
Clinical disease activity in the CALM study - Authors' replyJean-Frédéric Colombel, Remo Panaccione, Joel Petersson, et al.
American Journal of Rhinology|January 19, 2008
The effect of female hormone manipulation on nasal physiologyAnne M Robinson, Carl M Philpott, Julian A Gaskin, et al.
Inflammatory Bowel Diseases|October 25, 2011
Therapeutic drug monitoring of biologics for inflammatory bowel diseaseJean-Frédéric Colombel, Brian G Feagan, William J Sandborn, et al.
Inflammatory Bowel Diseases|February 26, 2011
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARERobert Löfberg, Edouard V Louis, Walter Reinisch, et al.
Inflammatory Bowel Diseases|May 13, 2009
Adalimumab safety in global clinical trials of patients with Crohn's diseaseJean-Frédéric Colombel, William J Sandborn, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|March 23, 2013
Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trialsWilliam J Sandborn, Jean-Frederic Colombel, Julian Panés, et al.
Journal of Crohn'S & Colitis|April 27, 2018
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE TrialsRemo Panaccione, William J Sandborn, Geert D'Haens, et al.
Pageof 5